Novartis says Cosentyx could be used as an early intervention in psoriasis after new data suggests it is the first drug of its kind to modify the course of the disease. The Swiss big pharma ...

Cosentyx belongs to a newer class of drugs that inhibit IL-17, and Novartis is aiming to encourage doctors to use it with longer term data showing that its benefits persist after five years, as ...

It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete ...

In 1626, Peter Minuit, a Westphalian and this colony’s first governor, bought New York for 60 guilders for about $24, which is nearly what a drink costs today at a ...